Colorectal Cancer | Specialty

Dr. Wiesner on Importance of Genetic Testing for CRC

December 28th 2015

Georgia L. Wiesner, MD, MS, director, Clinical and Translational Hereditary Cancer Program, Ingram Professor of Cancer Research, professor of Medicine, cancer geneticist, Vanderbilt-Ingram Cancer Center, discusses the importance of genetic testing for colorectal cancer.

Dr. Wu on Possible Combinations With TAS-102 in CRC

December 23rd 2015

Jennifer Wu, MD, assistant professor of Medicine, Department of Medicine, Perlmutter Cancer Center, NYU Langone Medical Center, discusses potential combinations with TAS-102 for the treatment of patients with colorectal cancer.

Dr. John Marshall on Steps to Finding a Cure for Colorectal Cancer

December 21st 2015

John Marshall, MD, Chief, Division Of Hematology/Oncology, Georgetown University Hospital Associate Director, Clinical Research, Lombardi Comprehensive Cancer Center at Georgetown University Hospital, discusses curing colorectal cancer.

Contemporary Evidence-Based Management of Newly Diagnosed Metastatic Colorectal Cancer

December 17th 2015

Contemporary efforts toward defining molecular subsets of colorectal cancer can potentially aid our ability to refine therapy and improve outcomes for patients with colorectal cancer.

Dr. Jennifer Wu on Immunotherapy in Mismatch Repair Deficient CRC

December 4th 2015

Jennifer Wu, MD, assistant professor of Medicine, Department of Medicine, Perlmutter Cancer Center, NYU Langone Medical Center, discusses the potential for immunotherapy in colorectal cancer with mismatch repair deficiency.

Dr. John Marshall on the Importance of Molecular Profiling in Colorectal Cancer

November 10th 2015

John Marshall, MD, Chief, Division of Hematology/Oncology, Medstar Georgetown University Hospital, Chief, Division Of Hematology/Oncology, Georgetown University Hospital Associate Director, Clinical Research, Lombardi Comprehensive Cancer Center at Georgetown University Hospital, discusses the importance of molecular testing in colorectal cancer.

Dr. Wu on Efficacy of Approved Agents in Colorectal Cancer

November 4th 2015

Jennifer Wu, MD, assistant professor of Medicine, Department of Medicine, Perlmutter Cancer Center, NYU Langone Medical Center, discusses the efficacy of regorafenib and TAS-102 for the treatment of patients with colorectal cancer.

Pembrolizumab Granted Breakthrough Status for Microsatellite Instability-High mCRC

November 2nd 2015

The FDA has granted a breakthrough therapy designation to pembrolizumab as a potential therapy for patients with microsatellite instability-high metastatic colorectal cancer.

Metastatic Colorectal Cancer: Expert Perspectives on Improving Care

October 30th 2015

Multidisciplinary Care in Advanced Colorectal Cancer

October 30th 2015

Treating Refractory Colorectal Cancer

October 30th 2015

The Genetics of Metastatic Colorectal Cancer

October 30th 2015

The Limitations of VEGF Inhibition in Colorectal Cancer

October 14th 2015

Leonard Saltz, MD, discusses antiangiogenesis and the use of VEGF inhibitors in colorectal cancer.

ASCO Releases Provisional Recommendation for RAS Testing in mCRC

October 10th 2015

ASCO has recommended extended RAS testing as a predictive biomarker of response for anti-EGFR monoclonal antibodies, further stressing the importance of broader molecular analyses for patients with metastatic colorectal cancer.

Dr. Dirk Arnold Discusses the CONSIGN Study

September 28th 2015

Dirk Arnold, MD, Director Department of Medical Oncology at Klinik für Tumorbiologie, Freiburg, Germany, Arnold Discusses the CONSIGN Study.

FDA Approves TAS-102, New Nivolumab Breakthrough Designation, Two Priority Reviews, and More

September 25th 2015

FDA Approves TAS-102 for Metastatic Colorectal Cancer

September 22nd 2015

The FDA approved the oral nucleoside TAS-102 (Lonsurf) for the treatment of patients with advanced colorectal cancer, based on results from the phase III RECOURSE trial.

USPSTF Recommends Aspirin for CRC Prevention in Draft Statement

September 17th 2015

The USPSTF has issued a draft guideline recommending the use of low-dose aspirin for the prevention of colorectal cancer and cardiovascular disease in adults aged 50 to 59 years.

Aspirin Reduces CRC Incidence in Individuals at Greatest Risk

September 15th 2015

Long-term aspirin use significantly lowered the risk of developing colorectal cancer in Lynch syndrome carriers while ameliorating the added risk associated with obesity.

Dr. Sinicrope on Mismatch Repair-Deficient Patients With Metastatic Colorectal Cancer

September 1st 2015

Frank A. Sinicrope, MD, medical oncologist, Departments of Gastroenterology and Hepatology and Oncology, Mayo Clinic, discusses patients with metastatic colorectal cancer (mCRC) who are mismatch repair-deficient.